Severe Influenza Trial of ARbidol

Influenza Clinical Trial

— STAR  

Official title:

Oseltamivir and Arbidol Combination Antiviral Therapy Versus Oseltamivir Monotherapy for the Treatment of Severe influenza: a Multicentre, Double-blind, Randomised Phase 3 Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03787459
• Other study ID #: CAP-China Arbidol
• Status: Recruiting
• Phase: Phase 3
• Start date: January 18, 2019
• Est. completion date: August 1, 2020

Study information

• Verified date: January 2019
• Source: Capital Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomised, double-blind, controlled study to assess the efficacy and safety of arbidol plus oseltamivir, compared with oseltamivir alone in approximately 200 hospitalized adults and adolescent patients with confirmed severe influenza. Patients should be randomised as soon as possible after screening (no later than 12 hours), providing they are within 7 days of symptom onset. Patients will be assigned in a 1:1 ratio to receive an arbidol plus oseltamivir, or oseltamivir plus placebo. Rescreening of patients who fail to meet the inclusion and exclusion criteria will be permitted only once, providing the time from symptom onset to randomization is still within 7 days.

Arbidol/placebo will be administrated as 200mg TID from Days 1-7. Oseltamivir will be administered as 75mg twice daily from Days 1-7 (dose to be adjusted for renal impairment). Oseltamivir could be continued till influenza PCR negative. Both drugs, along with the corresponding placebo for arbidol, will be started at the time of randomization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: August 1, 2020
• Est. primary completion date: March 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

1. Hospitalized males or females with a positive PCR test for influenza virus infection

2. Age =16 years at the time of signing Informed Consent Form

3. Arterial oxygen saturation (SaO2)/ pulse oxygen saturation (SPO2) =94% in room air condition

4. = 7 days since symptom onset. The onset of symptoms is defined as either: Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature- =38?); Time when the patient experiences at least one general or respiratory symptom.

5. Willingness to use contraception for 7 days after the end of treatment

Exclusion Criteria:

1. Physicians make a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.

2. Patient refusal to accept invasive organ support treatment if needed

3. More than 3 consecutive doses of NAIs within 2 days before enrolment (including oseltamivir, zanamivir, peramivir)

4. Women who are pregnant (including a positive pregnancy test at enrolment), breastfeeding, or within 2 weeks post-partum.

The following female subjects do not need to undergo a pregnancy test at enrolment: a. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test) women. b. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation.

5. Any condition requiring renal replacement therapy

6. Severe liver disease (Child-Pugh score = C)

7. A history of hypersensitivity to arbidol or oseltamivir (Tamiflu®)

8. Currently or have been involved in another anti-influenza treatment trial in the last 28 days

9. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Drug:
• Arbidol
Oseltamivir plus Arbidol will be administrated from Days 1-7.
• Placebos
Oseltamivir plus placebos will be administrated from Days 1-7.

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing	Beijing

Sponsors (4)

Lead Sponsor	Collaborator
Capital Medical University	National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Peking University, University of Oxford

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy endpoint was time to clinical status improvement (the event) up to 28 days	the event defined as seven-category ordinal scale of clinical status after enrolment decrease by two category or discharged	28 days